useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established
Valdez-Carrillo, M., Abrell, L., Ramrez-Hernndez, J., Reyes-Lpez, J
Health & Safety The Corporate Health and Safety team provides a range of occupational safety and health services, including advice on statutory guidance, safety action notices, safe working and training, incident reporting and investigation, including RIDDOR
Long-term metformin or proton pump inhibitor (PPI) users These medications can interfere with B12 absorption over time
